Adding quercetin or alpha-lipoic acid to metformin for women with PCOS
Official title: Impact of Adding Quercetin or Alpha Lipoic Acid as an Adjuvant Therapy on Clinical and Biochemical Outcomes in a Sample of Iraqi PCOS Patients
Run by Al-Mustansiriyah University · NCT07182526 · Data updated 2026-11-12
This trial will see if adding quercetin or alpha-lipoic acid to metformin improves hormones, blood sugar, cholesterol, and quality of life in women aged 18–40 with PCOS.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Al-Mustansiriyah University Academic / other |
| Locations | 1 site (Baghdad, Karkh) |
| Status | Recruiting |
| Started | September 20, 2025 |
| Main results expected | May 1, 2026 |
| Study ends | May 1, 2026 |
| Registry record updated | September 19, 2025 |
| Trial ID | NCT07182526 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women 18–40 with newly diagnosed PCOS defined by polycystic ovaries on ultrasound, oligomenorrhea, clinical or biochemical hyperandrogenism, normal prolactin, and no diabetes or other major endocrine or cardiovascular conditions.
✕Probably not a fit
Patients who are pregnant, have diabetes or other excluded comorbid endocrine or cardiovascular diseases, are already taking hormonal or lipid-lowering therapies, or cannot attend the Baghdad study site are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Women aged 18–40 with newly diagnosed PCOS will be randomly assigned for three months to one of three once-daily regimens: metformin alone, metformin plus quercetin (500 mg), or metformin plus sustained-release alpha-lipoic acid (600 mg). Fasting blood samples at baseline and month 3 will measure hormones, glucose/insulin, lipids, and oxidative-stress markers, while weight, blood pressure, and side effects will be recorded. Participants will complete the PCOSQ quality-of-life questionnaire and a 4-item medication adherence scale at both visits. The randomized, parallel-group design compares metabolic, hormonal, antioxidant, and patient-reported outcomes between regimens to judge safety and benefit.
Why it matters
Potential benefit: If successful, adding quercetin or ALA could offer a low-cost way to improve hormonal balance, metabolic health, and quality of life for women with PCOS.
How similar studies have gone: Small clinical and preclinical studies suggest quercetin and ALA can improve insulin resistance, lipid profiles, and oxidative-stress markers, but large randomized trials in PCOS are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Newly diagnosed patients should be at reproductive aged from 18-40 years. * Patients diagnosed with presence of micro polycystic ovaries at ultrasound. * Oligomenorrhea with inter-menstrual intervals longer than 35 days. * Clinical or biochemical signs of hyperandrogenism (acne, hirsutism). * Normal PRL levels. Exclusion Criteria: * • Presence of enzymatic adrenal deficiency and/or other endocrine disease, including diabetes. * Other comorbidities (such as hypertension, cardiovascular disease, or hormonal dysfunction). * Women who used oral contraceptives, hormonal therapy, or anti-lipidemic drugs. * Pregnant women.
Where it's running
-
Mustansiriyah University/ College of Pharmacy
Baghdad, Karkh, Iraq Recruiting
Study contacts
- Study coordinator: Mohammed Mahmood Mohammed, professor
- Email: pharm.drmhdclinical@uomustansiriyah.edu.iq
- Phone: 7816871131
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing letrozole alone versus letrozole with levothyroxine for women with PCOS and subclinical hypothyroidism
This study is testing if adding levothyroxine to letrozole helps women with PCOS and low thyroid function get pregnant more effectively than letrozole alone.
-
Using Semaglutide to Restore Ovulation in Young Women with PCOS
This study is testing if a medication called semaglutide can help young women with PCOS and obesity start ovulating again.
-
IVF outcomes for women with Polycystic Ovary Syndrome
This study looks at how well IVF and ICSI work for women with Polycystic Ovary Syndrome who are having trouble getting pregnant.
-
Using LC-MS/MS to profile androgens for PCOS diagnosis
This study tests whether LC-MS/MS measurement of androgen profiles can help diagnose PCOS in women compared with healthy controls.
-
Brown adipose tissue responses in PCOS with infrared thermography and inositol
This study tests whether brown fat activity, measured by infrared skin temperature and UCP-1 levels, differs among women with PCOS (normal weight or overweight/obese) and healthy controls, and whether 12 weeks of inositol changes those responses in overweight/obese PCOS participants.
-
Risk tool for blood-clotting problems in adolescents and women with PCOS
This project will try to build a risk model to spot decreased protein C or S and other clotting abnormalities in females aged 14–45 who have PCOS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.